Rekvina Laboratories Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 4,406 shares,. Its Average Traded Price (ATP) is ₹59.40, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2900 @ ₹59.40.
Rekvina Laboratories has an upper circuit limit of ₹59.40 and a lower circuit limit of ₹57.08. The total value traded stands at ₹2.62 L, and the delivery percentage for the day is 100%.
The stock is currently traded with a market lot size of 1. Rekvina Laboratories also offers a dividend yield of 0%.
Rekvina Laboratories Share Price Chart
Rekvina Laboratories Share Key Metrics
Volume
4406.00
Market Cap
35.11 CR
LTQ@LTP
2900@59.40
ATP
59.4
Var Margin
100 %
Circuit Range
57.08-59.4
Delivery %
100 %
Value
2.62 L
ASM/GSM
No
Market Lot
1
Rekvina Laboratories Resistance and Support
Pivot 58.24
Resistance
First Resistance
58.24
Second Resistance
58.24
Third Resistance
58.24
Support
First Support
58.24
Second Support
58.24
Third Support
58.24
Rekvina Laboratories Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Rekvina Laboratories Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-13 | Quarterly Results |
| 2026-05-21 | Audited Results |
| 2026-03-16 | Preferential Issue of shares |
| 2026-02-06 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-30 | Audited Results |
| 2025-01-20 | Quarterly Results |
| 2024-11-14 | Quarterly Results |
| 2024-07-29 | Quarterly Results |
Rekvina Laboratories News
Rekvina Laboratories Ltd - 526075 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Rekvina Laboratories' promoter and PACs significantly increased their shareholding by 31.34%, raising their total stake to 60.30%. This acquisition was executed through a combination of an open offer and preferential allotment, reflecting enhanced promoter confidence and control.
Aug 18 2026 10:41:46
Rekvina Laboratories Ltd - 526075 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Dhruvalkumar Patel acquired 1,112,562 equity shares in Rekvina Laboratories, bringing his total holding to 10.01% of the company's voting capital. This acquisition was done through a combination of an open offer and preferential allotment on August 12-13, 2026.
Aug 17 2026 15:15:05
Rekvina Laboratories Ltd - 526075 - Board Meeting Outcome for OUTCOME OF BOARD MEETING
Rekvina Laboratories reported a Q1 FY27 standalone net loss of ₹0.12 crore, significantly widening from the ₹0.03 crore loss recorded in Q1 FY26. Additionally, the board appointed Surbhit Shah as the Executive Director and Chairman.
Aug 13 2026 15:47:52
Rekvina Laboratories Ltd - 526075 - Announcement under Regulation 30 (LODR)-Allotment
Rekvina Laboratories allotted 46.28 lakh equity shares on a preferential basis for the acquisition of Radiant Parenterals Limited, which will become a wholly-owned subsidiary. An additional 4.60 lakh shares were allotted for cash consideration of Rs.46 lakh.
Aug 12 2026 17:27:09
Rekvina Laboratories Management
| Name | Position |
|---|---|
| Amit Shah | Managing Director |
| Deepak Khandelwal | Company Secretary & Compliance Officer |
Rekvina Laboratories FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in VINRKLB
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
+ Free 1st Year AMC